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Summary (309 words; maximum, 250) 
Background  Systemic sclerosis (SSc) is a rare disabling autoimmune disease with few 
treatment options. The efficacy and safety of the interleukin-6 receptor-α inhibitor 
tocilizumab were assessed in the faSScinate phase 2 trial in patients with SSc. 
Methods  This global, double-blind, placebo-controlled study enrolled adult patients with 
progressive SSc of ≤5 years’ duration from first non-Raynaud sign or symptom. Patients were 
randomly assigned (1:1) to weekly subcutaneous tocilizumab 162 mg or placebo for 48 
weeks. The primary efficacy endpoint was the difference in mean change from baseline in 
modified Rodnan skin score (mRSS) at week 24. Gene expression analysis was performed on 
skin biopsy specimens collected at baseline and week 24. Cartilage oligomeric matrix protein, 
periostin, autotaxin, and CCL18 serum levels were determined using immunoassays. 
Findings  Eighty-seven patients received tocilizumab (n=43) or placebo (n=44). The primary 
endpoint showed a treatment difference of –2·70 mRSS units (95% CI: –5·85, 0·45) in favour 
of tocilizumab at week 24 but did not meet statistical significance (p=0·0915). At week 48, 
the treatment difference was –3·55 mRSS units (95% CI: −7·23, 0·12), favouring tocilizumab 
over placebo (p=0·0579). Exploratory analysis of lung function showed that fewer patients in 
the tocilizumab arm had a decline in percent predicted forced vital capacity than in the 
placebo arm by comparison of the cumulative distribution (week 48, p=0·0373). Tocilizumab 
downregulated the expression of myeloid-associated genes in the skin and decreased 
circulating levels of CCL18, a chemokine associated with fibrosis and progression of SSc-
associated lung disease. Proportion of patients with adverse events/serious adverse events 
were not different between tocilizumab (42/43 [97·7%]/14/43 [32·6%]) and placebo (40/44 
[90·9%]/15/44 [34·1%]), but those with serious infections were higher in the tocilizumab 
group (7 patients) vs. in the placebo group (2 patients). 
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Interpretation  Tocilizumab was associated with a numerical reduction in skin thickening 
and less decline in forced vital capacity. These efficacy outcomes along with safety data and 
insights into the potential mechanism of action of tocilizumab support pursuing a phase 3 
study. 
Funding  F. Hoffmann-La Roche/Genentech (ClinicalTrials.gov, number NCT01532869).  
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Introduction 
Systemic sclerosis (SSc) is a rare connective tissue disorder characterised by fibrosis, 
inflammation, and microvascular injury with heterogeneous clinical presentations. 
Pulmonary, cardiac, gastrointestinal (GI), and renal complications contribute to patient 
morbidity and decreased survival.
1
 
Increasing evidence supports important roles for interleukin-6 (IL-6) in the 
pathogenesis of SSc,
2
including B-cell differentiation towards immunoglobulin-secreting 
plasma cells, T-cell differentiation towards Th17 and Th2 cell types, and transformation of 
fibroblasts to myofibroblasts leading to extracellular matrix synthesis.
2
  In patients with SSc
3
 
or SSc-interstitial lung disease (ILD), increased IL-6 levels have been associated with higher 
mortality, more severe skin involvement, and increased incidence of progressive pulmonary 
decline.
4
 Although the exact cellular mechanisms of the effects of IL-6 on fibrosis are 
unknown, myeloid cells are implicated in SSc skin pathogenesis.
5
 mRNA expression of a 
cluster of macrophage genes, including CD14 in the skin, correlates strongly with modified 
Rodnan skin score (mRSS), and CD14 expression is prognostic for progressive skin disease.
6
 
M2 macrophages appear to play an important role in mediating inflammation and promoting 
fibrosis through the release of profibrotic factors.
7,8
 
Blockade of the IL-6 pathway reduced skin fibrosis, smooth-muscle actin protein 
expression,
9
hydroxyproline content, and myofibroblast counts in the bleomycin mouse 
model.
10
 Initial data in SSc patients indicated that treatment with tocilizumab improved skin 
sclerosis and SSc-associated polyarthritis.
11,12
 Certain circulating biomarkers are associated 
with the cardinal features of SSc, namely fibrosis, vasculopathy, and inflammation. Autotaxin 
(ENPP2) is an IL-6-induced biomarker associated with the development of fibrosis that is 
elevated in the circulation of SSc patients
13
. ENPP2 catalyzes production of lysophosphatidic 
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acid (LPA)
14
and elevated levels of circulating LPA have been associated with the 
pathobiology of SSc.
15,16
 Serum levels of cartilage oligomeric matrix protein (COMP) 
correlate with skin fibrosis and predict mortality in SSc patients.
17
 Elevated serum levels of 
chemokine (C-C motif) ligand 18 (CCL18) are associated with scleroderma-associated 
pulmonary fibrosis and ILD progression,
18,19
 and elevated serum levels of periostin (POSTN) 
are associated with the degree of skin fibrosis in patients with SSc.
20
   
The faSScinate phase 2 trial was conducted to investigate the efficacy and safety of 
IL-6 blockade with tocilizumab in SSc and to perform exploratory analysis of biomarkers. 
 
Methods 
Study design and participants  
This randomised, double-blind, placebo-controlled study was conducted in 35 centres across 
Canada, France, Germany, the United Kingdom, and the United States. Investigators from 
each centre enrolled eligible patients 18 years of age or older who met the 1980 American 
College of Rheumatology criteria for SSc21 with ≤5 years’ disease duration since their first 
non-Raynaud sign or symptom and mRSS from 15 to 40 units. At screening, active 
progressive disease of <1 year’s duration was required—increase of ≥3 mRSS units, 
involvement of one new body area with increase in mRSS ≥2 units or two new body areas 
with increase in mRSS ≥1 unit, other documentation of worsening skin thickening in the 
previous 6 months, or ≥1 tendon friction rub plus ≥1 laboratory criterion (C-reactive protein 
[CRP] ≥10·0 mg/L, erythrocyte sedimentation rate ≥28 mm/h, or platelets ≥330×1000/L). 
All patients provided written informed consent. Patients or their caregivers could provide 
subcutaneous (SC) investigational product injections. Eligible patients had clinically 
uninvolved skin at, at least one body areas for study drug injections.  
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Each site’s institutional review board/ethics committee approved the protocol before the 
study commenced. The study was conducted in accordance with the Declaration of Helsinki 
and with Good Clinical Practice.  
Randomisation and masking 
Patients were randomly assigned (1:1) using an interactive voice/web response system to 
receive weekly subcutaneous treatment with tocilizumab 162 mg or placebo for 48 weeks 
followed by open-label weekly tocilizumab for 48 weeks. Randomisation numbers were 
generated by the sponsor, and randomisation was stratified by joint involvement at baseline 
(<4 or ≥4 joints on the 28 tender joint count). Investigators, patients, and sponsor personnel 
were blinded to treatment assignment. To prevent potential unblinding due to observed 
efficacy or laboratory changes, separate assessors evaluated efficacy and safety. Both 
assessors were blinded to treatment assignment. The efficacy assessor did not have access to 
any patient safety or laboratory data during the double blind phase of the trial. However, the 
safety assessor had access to efficacy, as well as safety data. Although some sponsor 
personnel were unblinded after the primary analysis at week 24, the treatment blind was 
maintained for personnel interacting with sites and site staff until the week 48 database lock.  
Procedures 
Escape therapy with methotrexate, hydroxychloroquine, or mycophenolate mofetil was 
permitted after week 24 for patients with ≥20% worsening mRSS from baseline, worsening 
SSc-associated complications such as arthritis and ILD, or both, as determined by the treating 
investigator. The primary endpoint was the difference in mean change from baseline in mRSS 
to week 24. Secondary endpoints included patient-/physician-reported outcomes to weeks 24 
and 48 (Health Assessment Questionnaire–Disability Index [HAQ-DI] score, patient global 
visual analogue scale [VAS, 0-100], physician global VAS, Functional Assessment of 
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Chronic Illness Therapy [FACIT]-Fatigue score, and pruritus 5-D Itch), change from baseline 
in mRSS to week 48, proportion of patients with change from baseline in the mRSS at Week 
48 greater than or equal to the change from baseline in the mRSS at Week 24, change in VAS 
scores from baseline (intestinal, breathing, Raynaud’s, finger ulcers, overall disease VAS 
scores from SHAQ-DI). Exploratory endpoints included proportion of patients achieving 
minimum clinically important difference (change ≥0.22) in the HAQ-DI at week 48, 
proportion of patients with 20%/40%/60% improvement in mRSS at weeks 24 and 48, 
change from baseline at weeks 24 and 48 in pulmonary function measured by forced vital 
capacity (FVC; mL), percent predicted FVC (%pFVC), and percent predicted diffusing 
capacity for carbon monoxide (%pDLCO) and change from baseline at week 24 and 48 in 28 
TJC in patients with joint involvement at baseline (defined as ≥4 tender joints).  Safety 
monitoring for adverse events (AEs) and serious AEs (SAEs) and laboratory monitoring were 
performed at least every 8 weeks. Exploratory biomarker analyses included gene expression 
analysis of skin biopsy specimens collected at baseline and at week 24 and COMP, POSTN, 
and CCL18 serum levels determined using immunoassays (see appendix). 
Statistical analyses 
A sample size of 36 patients per group (86 patients total, allowing for 15% dropout) was 
determined to provide 80% power to detect a difference in means for the change in mRSS 
from baseline to week 24 of 4·7 units, based on an estimated common standard deviation of 
6·99
22
 using a two-group t-test with a 5% two-sided significance level.  
The primary endpoint was analysed using a mixed-model repeated-measures 
(MMRM) approach. There was no imputation of missing data before the MMRM analyses, 
and all were stratified by joint involvement at baseline. Patients discontinuing their treatment 
before week 24 had their last evaluation at the time of discontinuation. Except for exploratory 
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analysis of pulmonary function, which included all available data, all week 48 MMRM 
analyses of secondary endpoints used data that were censored after initiation of escape 
therapy. The MMRM approach assumes that data are missing at random; therefore, 
sensitivity analyses were performed on the primary endpoint to account for data that might 
not have been missing due to random chance (appendix table 1).  
Patients with a missing mRSS assessment at week 24 or week 48 were considered 
non-responders for analysis of 20/40/60% improvement in mRSS from baseline. Similarly a 
non-responder approach was used for the MCID of the HAQ-DI and the maintenance of 
mRSS response at week 48. The van Elteren test (stratified by joint involvement) was used to 
compare the treatment effect on the cumulative distribution of change from baseline in 
%pFVC and %pDLCO.There was no adjustment for multiplicity in statistical testing for any 
of the analyses. For SAE rates per 100 patient-years, multiple occurrences of events in a 
patient were counted, and the confidence intervals were based on the Poisson distribution. 
The analysis population for efficacy was the modified intent-to-treat (mITT) population, 
which included all randomly assigned patients that received any study drug. No randomized 
patients were excluded from the mITT. The safety population included all patients that 
received study drug and provided at least one post-dose safety assessment. Again this 
included all randomized patients. 
Role of the funding source 
The sponsor designed the study in collaboration with the authors. The sponsor collected, 
analysed, and interpreted the data and drafted the report. All authors contributed to data 
interpretation, revised the manuscript, and attest to the accuracy and completeness of the 
reported data. The corresponding author had full access to all data congregates in the study 
and made the final decision to submit the manuscript for publication. 
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Results 
Patients were randomly assigned from March 13, 2012, to June 18, 2013; the last patient 
completed the week 48 visit on May 19, 2014. Eighty-seven patients were randomly assigned 
to treatment and were included in the intent-to-treat and safety populations (figure 1). At 
week 48, 12 of 44 placebo-treated patients and 6 of 43 tocilizumab-treated patients had 
received escape therapy. The numbers of patients who withdrew were similar between 
treatment arms: tocilizumab—safety (n=8 [five AEs, three deaths]), non-safety (n=5 [three 
patient decision, one lack of efficacy, one lost to follow-up]); placebo—safety (n=4 [AEs]), 
non-safety (n=7 [five patient decision, one clinician decision, one non-compliance]). Baseline 
demographics and disease characteristics as well as dose intensity of the investigational 
treatment were well balanced between treatment arms (table 1).  
The primary endpoint was not met at week 24. A numerically larger, but not statistically 
significant, improvement in mRSS was seen with tocilizumab compared with placebo (table 
2, figure 2). Least-squares mean (LSM) change in mRSS from baseline to week 24 was –3·92 
in tocilizumab patients and –1·22 in placebo patients (treatment difference, –2·70 [95% 
confidence interval (CI): –5·85, 0·45]; p=0·0915). The observed mean (SD) mRSS at week 
24 was 21·84 (9·89) for tocilizumab (n = 37) and 23·21 (9·26) for placebo (n = 38). Results 
through week 48 showed a continued numerically larger treatment benefit beyond 24 weeks, 
with LSM change from baseline was –6·33 with tocilizumab and –2·77 with placebo 
(treatment difference, −3·55 [95% CI: −7·23, 0·12]; p=0·0579) (table 2, figure 2). The 
observed mean (SD) mRSS at week 48 was 19·56 (10.08) for tocilizumab (n = 32) and 22·27 
(8·05) for placebo (n = 33). Among improvers in mRSS at Week 24, more tocilizumab 
patients maintained or had further improvement in their mRSS at week 48 compared to 
placebo (placebo: 8 of 18 patients [44.4%] and tocilizumab: 15 of 22 patients [68.2%]).  At 
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week 48, a numerically higher proportion of patients receiving tocilizumab had mRSS 
improvement of at least 20%, 40%, or 60% compared with placebo (figure 2).  
For patient- and physician-reported outcomes at weeks 24 and 48, the treatment 
difference between tocilizumab and placebo patients in LSM change from baseline was not 
statistically significant. For clinician and patient global VAS and FACIT-fatigue scores, 
favourable responses for tocilizumab compared to placebo were observed at week 48 (table 
2). For the HAQ-DI result at week 48—though not statistically significant—the treatment 
difference of –0·207 (95% CI: –0·471, 0·056; p=0·1212) favoured tocilizumab versus 
placebo. In addition, at week 48, a numerically higher proportion of patients receiving 
tocilizumab than placebo achieved an improvement of ≥0·22 in HAQ-DI (28% vs 7%, 
respectively; p=0·0111), with identical results for improvement defined as ≥0.14. Overall, 
with the exception of the breathing VAS score, all other SHAQ VAS scores (intestinal 
disease, Raynaud syndrome, digital ulcers, and overall disease) at week 48 showed a 
numerical, however not statistically significant, difference between treatment groups favoring 
tocilizumab; (See appendix and Table S3).  
Twenty-one patients in the tocilizumab and 20 patients in the placebo arm had joint 
involvement defined as ≥ 4 tender joints at baseline. Over the 48-week treatment-blinded 
period, mean (median) tender joint counts declined from baseline by 4.3(2.5), (n=16) and 
5.10 (4.5) (n=10) in the TCZ arm and 2.1 (2.0), (n=17) and 2.9 (2.5) (n=12) in the PBO arm 
amongst patients with joint involvement at weeks 24 and 48 respectively.  
Patients with SSc are at risk to develop ILD and progressive decline in FVC.
23
 Pulmonary 
function testing showed, on average, a smaller decrease in FVC from baseline for tocilizumab 
than for placebo at weeks 24 (LSM difference, 136 mL [95% CI: 9, 264]; p=0·0368) and 48 
(LSM difference, 120 mL [95% CI: –23, 262]; p=0·0990) (figure 3A).Cumulative 
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distribution plots of change from baseline in %pFVC at weeks 24 (figure 3B) and 48 (figure 
3C) indicated that fewer tocilizumab than placebo patients experienced worsening of %pFVC 
(p=0·009, week 24; p=0·0373, week 48). At weeks 24 and 48, respectively, 3% and 10% of 
tocilizumab-treated patients compared with 19% and 23% of placebo-treated patients 
experienced >10% (absolute) decreases in %pFVC from baseline. LSM changes from 
baseline in %pFVC for tocilizumab versus placebo at weeks 24 and 48, respectively, were –
0·7 (95% CI: –3·2, 1·8) versus –4·5 (95% CI: –7·0, –1·9) and –2·6 (95% CI: –5·2, –0·1) 
versus –6·3 (95% CI: –8·9,-3·8). At week 48, change from baseline in %pDLCO did not 
reveal differences between placebo and tocilizumab (appendix figure 1). Correlations 
between improvements in mRSS and change in %pFVC from baseline to week 48 were 
similar for both treatment arms (tocilizumab, r=–0·311, p=0·121; placebo, r=–0·278, 
p=0·223; appendix figure 2). Correlations between baseline CRP and change in mRSS over 
week 48 were xxxx for both treatment arms (tocilizumab, r=–0·xx, p=xx; placebo, r=yy, 
p=yy). Among patients with available week 48 mRSS data, 4 of 32 (13%) tocilizumab-treated 
patients and 9 of 33 (27.3%) placebo-treated patients received escape therapy.  
Exploratory analysis of the circulating biomarkers COMP, POSTN, ENPP2, and CCL18 was 
conducted on serum samples from all available patients and time points using specific 
immunoassays (figure 4).  The serum levels of COMP, POSTN, ENPP2, and CCL18 at 
Baseline were all significantly elevated compared to age and gender matched Healthy 
Volunteers (COMP p < 0.0001, POSTN p < 0.0001, ENPP2 p < 0.0001, CCL18 p < 0.0001; 
two-tail t-test assuming unequal variance). Treatment with tocilizumab resulted in a 
significant decrease in serum levels of CCL18 (figure 4A) whereas tocilizumab had no 
apparent effect on COMP (figure 4B), POSTN (figure 4C), or ENPP2 (figure 4D). 
Exploratory gene expression analysis was conducted on skin biopsies collected at baseline 
and week 24 from the forearm region of a subset of patients (placebo baseline = 39, placebo 
13 
 
week 24 = 30,  tocilizumab baseline = 34, and tocilizumab week 24 = 28) and of 20 age-and 
gender-matched healthy volunteers.  First, Gene Set Enrichment Analysis (GSEA) for 
Fibrosis-, IFN-, IL-6-, TGF-, M1 Macrophage-, and M2-Macrophage-gene sets 
(Supplementary tables S4, S5, S6, S7, S8, and S9, respectively) was conducted on the 
microarray data obtained from all available samples. While the expression levels of the 
Fibrosis-, IFN-, IL-6-, TGF-, M1 Macrophage-, and M2 Macrophage-gene sets were 
significantly higher in the SSc samples compared to the HV samples (p(seeing t <= observed) 
= 1.000, p(seeing t >= observed) = 0.005 for all), no significant difference in expression 
levels was detected in the TCZ Week 24 samples compared to tocilizumab Baseline samples.  
However, we observed non-significant trends in reduction of expression levels between 
tocilizumab Week 24 and tocilizumab Baseline in the IFN- (p(seeing t <= observed) = 0.070, 
p(seeing t >= observed) = 0.935), IL-6- ((p(seeing t <= observed) = 0.095, p(seeing t >= 
observed) = 0.910), and M2 Macrophage-gene sets ((p(seeing t <= observed) = 0.105, 
p(seeing t >= observed) = 0.900), motivating us to investigate further these pathways. 
Next, based on a genome-wide analysis of gene expression in these biopsies, a set of 83 genes 
was selected (see supplementary material) for confirmatory analysis using nCounter 
technology (Nanostring Technologies; figure 5) Out of these 83 genes representing the 
Fibrosis/TGF-, IL-6, IFN, and Myeloid pathways, 62 transcripts were significantly over 
expressed and 2 were significantly under expressed in SSc patients vs. HV (t-test, Bonferroni 
correction for multiple comparisons).  Clustering analysis of the average gene expression 
(Log10 transformed and Normalized) for the placebo Baseline, placebo Week 24, tocilizumab 
Baseline, and tocilizumab Week 24 groups yielded 9 clusters representing the TGF- , IL-
6/STAT3 , M1-Macrophage, M2-Macrophage , and IFN pathways based on the classification 
provided by Ingenuity Pathway Analysis (Qiagen, USA; figure 5).  Analysis of the effect of 
treatment on the change in gene expression levels at week 24 identified 16 genes specifically 
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down regulated by tocilizumab vs. placebo (Uncorrected p< 0.05 ANCOVA on change in 
gene expression levels at week 24 with Baseline Expression Level as linear covariate and 
Treatment as categorical classifier). While the majority of these genes (12/16) belonged to the 
“M2 Mac” cluster, two genes belonged to the “M1 Mac” cluster, suggesting an inhibitory 
activity of tocilizumab on macrophage in general and M2 macrophage in particular.  
Although gene expression in the “IL-6/STAT3” cluster tended to be reduced by tocilizumab 
at week 24 compared to placebo, only two genes (CCL2 and SOCS3) were significantly 
down regulated by tocilizumab vs. placebo, possibly reflecting the substantial heterogeneity 
in gene expression across patients.  
Finally, using the same data set, we tested the differential effect of treatment with tocilizumab 
on a recently developed multi-analyte, longitudinal pharmacodynamic biomarker (2GSSc 
skin biomarker
24
).  This biomarker, which yields predicted mRSS values based on the 
weighted values for THBS1 and MS4A4A mRNA expression values, was validated and has 
been applied to two clinical trials, indicating that it is a robust surrogate outcome measure for 
the extent of SSc skin disease.
25
  At Baseline, the predicted mRSS values were similar 
between the placebo and tocilizumab groups (placebo Mean [95% CI]: 16.4 [15.1 – 17.8]; 
tocilizumab Mean [95% CI]: 15.5 [14.1 – 17.0]; figure 6).  Comparison of the change in 
predicted mRSS at Week 24 between placebo and tocilizumab indicated that treatment with 
tocilizumab resulted in a significant decrease in predicted mRSS as compared to treatment 
with placebo ( placebo Mean [95% CI]: -0.98 [- 2.99 – 1.03];  tocilizumab Mean [95% 
CI]: -4.03 [-7.58 – - 0.49]; p = 0.0488; figure 6). 
 
Safety 
15 
 
At weeks 24 and 48, the proportion of patients with AEs in the tocilizumab (38/43 [88·4%]; 
42/43 [97·7%]) and placebo (40/44 [90·9%]; 40/44 [90·9%]) arms were comparable, as were 
withdrawal rates due to AEs (table 3). The most frequently reported AEs included infections, 
GI disorders, skin/subcutaneous disorders, and musculoskeletal/connective tissue disorders 
(appendix table 10). Serious infections were more frequent with tocilizumab (seven patients) 
than placebo (two patients), whereas non-infectious SAEs, including cardiac disorders, GI 
disorders, and renal and urinary disorders, were more frequent with placebo. Osteomyelitis 
involving proximal interphalangeal joints occurred in two tocilizumab patients and one 
placebo patient. No anaphylaxis, GI perforations, or malignancies were observed and SC 
injections were well tolerated. Total exposure to study drug before open-label treatment in 
patient-years (PY) was 34·49 for tocilizumab and 36·77 for placebo. The overall SAE rate 
was 66·7% (95% CI: 42·3, 100·1)/100 PY with tocilizumab and 76·1 (95% CI: 50·6, 
110·0)/100 PY with placebo, the serious infection rate was 34·8 (95% CI: 18·0, 60·8)/100 PY 
and 10·9 (95% CI: 3·0, 27·9)/100 PY, and the rate of noninfectious SAEs was 31·9 (95% CI: 
15·9, 57·1)/100 PY and 65·3 (95% CI: 41·8, 97·1), respectively.   
Four deaths were reported by week 48.One placebo patient died of cardiac failure, and three 
tocilizumab patients died of one event each of arrhythmia, multiorgan failure, and lung 
infection. Only one event, lung infection, was considered related to study drug. (For details 
see appendix) 
 
Laboratory parameters of interest for tocilizumab (elevated alanine/aspartate 
aminotransferase, decreased neutrophils, and decreased platelets) were mostly grade 1/2 in 
intensity and were not temporally associated with clinically relevant sequelae such as hepatic 
events, serious infections, or serious bleeding events.  
16 
 
 
Discussion 
In this first phase 2 randomised controlled trial of tocilizumab for the treatment of SSc, the 
primary (mRSS) and secondary efficacy endpoints were not met at week 24 or 48. However, 
consistent improvements in skin thickness through week 48 in the tocilizumab arm were 
evident, with mRSS improvement at weeks 24 and 48 within published minimal clinically 
important differences for early, diffuse SSc.
26
 HAQ-DI, clinician global VAS, and other 
patient-reported outcomes favored tocilizumab over placebo, though they did not reach 
statistical significance. Significantly fewer patients receiving tocilizumab had absolute FVC 
declines of >10% compared with patients receiving placebo.  
The current study shows a clinically meaningful decline in mRSS
26
 over 1 year in the 
tocilizumab group compared with the placebo group. Careful selection of patients with early 
progressive disease might have been important to observe this effect. Skin thickness is a 
surrogate marker for internal organ involvement and mortality in SSc, and patients with 
attenuated skin thickness have improved survival and physical function.
27,28
Conversely, 
patients with high mRSS have greater internal organ involvement
29
 and are at greater risk for 
death.
27
 
SSc has the highest case fatality among rheumatic diseases, with a cumulative survival 
from diagnosis of 74.9% at 5 years.
30
 Cardiopulmonary involvement is the leading cause of 
death,
1
and FVC is the primary outcome measure in most SSc-ILD and idiopathic pulmonary 
fibrosis trials.
31
 Elevated CRP levels have been associated with progressive ILD, and 
observational cohorts suggest that baseline elevated CRP predicts long-term FVC decline.
3,32
 
Although our study was not specifically designed to enroll patients with progressive SSc-
ILD, enrolling patients with early progressive skin disease and elevated acute-phase reactants 
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likely enriched for SSc patients at high risk for ILD. Our data suggest that tocilizumab may 
have a disease-modifying effect by slowing the decline in lung function of patients with SSc.  
Treatment with tocilizumab resulted in the specific downregulation of skin myeloid– 
associated genes, including M2-macrophage–associated genes. Perivascular macrophages 
(resident and/or recruited) contribute to vascular inflammation,
33
 and M2-macrophages may 
play an important role in SSc skin pathology through the release of inflammatory and 
profibrotic factors.
8
 It is therefore tempting to speculate that the improvement in skin disease 
in patients treated with tocilizumab  may be due to the inactivation and/or depletion of skin 
macrophages in general and M2-macrophages in particular. Furthermore, treatment with 
tocilizumab resulted in rapid, sustained reductions in serum levels of the M2-macrophage–
associated chemokine CCL18, strengthening the hypothesis that tocilizumab may act, at least 
in part, by modulating the activity of M2-macrophages. Given that serum CCL18 is a 
prognostic biomarker that identifies patients at higher risk for the progression of scleroderma 
lung disease,
18
 it is possible that the effect of tocilizumab on circulating CCL18 may be 
related to the positive clinical effect of tocilizumab on lung function deterioration. These 
hypotheses will be further explored in the ongoing phase 3 study of tocilizumab in SSc 
patients. 
 
Tocilizumab did not affect the serum levels of ENPP2, COMP and POSTN, three 
biomarkers related to fibrosis, suggesting that the effect of tocilizumab on mRSS is not 
directly due to change in the expression of these fibrotic markers. It is also possible that these 
fibrosis-related biomarkers are not sensitive measures of clinical improvement in skin fibrosis 
or may require additional time to show significant improvements. Finally, in keeping with the 
clinical effect of tocilizumab on skin fibrosis as measured by mRSS, treatment with 
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tocilizumab resulted in a significant decrease in the 2-Gene SSc Skin Biopsy predicted 
mRSS. Of note, the magnitude of change in predicted mRSS was similar to that observed 
clinically.      
Overall, after 48 weeks of treatment, safety in faSScinate was consistent with the natural 
history of SSc and the known safety profile for tocilizumab (table 3, appendix table 10). 
Reflecting the high morbidity and mortality rates seen in SSc,
1
greater incidences of SAEs, 
serious infections, and deaths were seen in faSScinate than in clinical trials of tocilizumab in 
RA.  
There were 3 deaths in the tocilizumab group vs. 1 in the placebo group, with only one 
death judged as related to tocilizumab by the study investigator. Based on the higher number 
of deaths in faSScinate on tocilizumab compared to placebo, it will be important to carefully 
assess the mortality rates as well as cause of death during the phase 3 tocilizumab study in 
SSc that has just been initiated. 
 Furthermore a higher rate of serious infections was observed in the tocilizumab arm. The 
serious infections observed include bronchititis, lung infection, pneumonia and sepsis, which 
are similar to the types of events observed during treatment with tocilizumab in RA. 
However, small bone osteomyelitis and infected digital ulcers are infections not commonly 
observed during therapy with tocilizumab in patients with RA and thus may require particular 
vigilance in patients with SSc.  
Although the GI tract is the most frequently affected internal organ in patients with SSc,
1
 
no patients in faSScinate had GI perforations. Injection site reactions, elevations in 
alanine/aspartate aminotransferase levels, and decreases in neutrophil and platelet counts 
were mostly grade 1/2 and involved no clinically relevant sequelae. 
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No disease-modifying therapy is yet approved for SSc, and its management is based on 
organ involvement.
34,35
 Methotrexate affected skin thickening without establishing positive 
effects in patients with other organ manifestations,
34,36
 whereas oral cyclophosphamide 
modestly improved lung function and skin thickness in studies of patients with SSc-ILD.
37
 
Recent data from a clinical trial
38
 in haematopoietic stem cell transplantation suggested a 
disease-modifying effect in patients with SSc; thus, haematopoietic stem cell transplantation 
may be considered an option for selected patients with rapidly progressing and severe SSc. 
Data from this trial suggest that tocilizumab may have a broader effect on SSc skin and lung 
disease than methotrexate and a more favourable risk/benefit profile than cyclophosphamide.  
Limitations of this study include selection of week 24 for the primary endpoint based on 
the assumption that the rapid response of tocilizumab seen in clinical trials of RA would 
translate to a rapid response in patients with SSc. The relatively high discontinuation rate 
should be taken into account when interpreting data from this study. FVC was an exploratory 
endpoint, and high-resolution chest tomography, which was not performed to substantiate the 
pulmonary function data, is planned for a phase 3 study. Cohort enrichment of patients with a 
probability of skin progression and elevated acute phase reactants may have contributed to 
the treatment responses observed.  Whether the results are generalizable to other patients with 
SSc will require further study 
 
Conclusion 
faSScinate is the first placebo-controlled study in SSc demonstrating improvement of skin 
sclerosis, albeit not statistically significant, and a clinically relevant improvement in lung 
function, with an acceptable safety profile. The safety profile was consistent with known SSc 
complications and the safety profile of tocilizumab. The propensity of SSc patients to develop 
20 
 
digital ulcers could increase susceptibility to develop small bone osteomyelitis and infections 
of digital ulcers during TCZ therapy. Overall, the data suggest a positive risk/benefit profile 
for tocilizumab in SSc, warranting further investigation.  
 
Research in Context  
Evidence before this study 
In vivo data demonstrating elevated IL-6 levels in serum and skin biopsy samples of patients 
with SSc, associated with greater disease activity and higher mortality rates, provided 
evidence that IL-6 may play an important role in the pathogenesis of SSc. In addition, serum 
IL-6 levels in patients with early SSc have been shown to predict the extent of future 
progression of skin disease. Supportive evidence for a role of IL-6 in skin fibrosis was 
provided by the bleomycin-induced mouse model of scleroderma in which an IL-6 blocking 
antibody reduced dermal sclerosis in both a prevention model and a therapeutic model. 
Furthermore, the extent of fibrosis was attenuated in IL-6 knockout mice. Additional 
preliminary evidence of efficacy came from two therapy-refractory patients with SSc, who 
experienced improvement in skin thickening after treatment with tocilizumab for 6 months. 
Myeloid cells have been increasingly implicated in SSc skin pathogenesis. In particular, 
alternatively activated macrophages appear to play an important role in the pathobiology of 
SSc by mediating fibrosis through the release of profibrotic mediators such as CCL18. 
Several literature searchs through the US National Library of Medicine, National Institutes of 
Health were conducted prior to protocol finalization 23 August 2011. These included the 
search terms “systemic sclerosis”, or “scleroderma” as well as a combination of systemic 
sclerosis with any of the following search terms: IL-6, biomarkers, CCL-18, review, modified 
Rodnan skin score, clinical trials and interstitial lung disease. In addition, standard English 
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language rheumatology text books were reviewed and an advisory board with experts in the 
field of systemic sclerosis was convened. 
 
Added value of this study 
This is the first placebo-controlled study in patients with early SSc to show efficacy, as 
evidenced by a clinical, however not a statistically significant amelioration of skin sclerosis, 
better patient-reported outcomes, and clinically relevant improvement in lung function in 
patients treated with the anti–IL-6 receptor-alpha inhibitor tocilizumab. Tocilizumab had an 
acceptable safety profile in these patients. The biomarker findings suggest that tocilizumab 
may ameliorate SSc skin disease by inhibiting skin myeloid cells in general and alternatively 
activated macrophages in particular. 
 
Implications of all the available evidence 
Given the lack of disease-modifying treatment options for patients with SSc, combined with 
the morbidity and mortality associated with this disease, data from the faSScinate trial 
provide hope regarding a potential future treatment for patients with SSc. faSScinate was a 
phase 2 study; therefore, the efficacy and safety of tocilizumab must be further investigated 
in an adequate, randomised, well-controlled phase 3 trial before definitive conclusions can be 
drawn about its risk/benefit profile. 
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TABLES AND FIGURES 
 
 Placebo 162 mg qw 
SC 
n=44 
Tocilizumab 162 mg qw 
SC 
n=43 
Age, years 48 (12·9) 51 (11·7) 
Female, n (%) 35 (80) 32 (74) 
White, n (%) 40 (91) 38 (88) 
Mean duration of SSc,
a
 months 19·5 (17·0) 17·6 (13·9) 
Anti-RNA polymerase antibody 
positive, n (%) 
17 (38·6) 13 (30·2) 
Previous biologic agents, n (%) 2 ( 4.5) 0 
Previous immunosuppressive agents, n 
(%) 
5 ( 11.4)  1 ( 2.3) 
Previous/concomitant 
prednisone/corticosteroid use, n (%)
b 
18 (40.9) 25 (58.1) 
Anti-topoisomerase antibody positive, 
n (%) 
20 (45·5) 18 (41·9) 
Patients with ≥1 tendon friction rub, n 
(%) 
22 (50.0) 20 (46.5) 
TJC28 ≥4, n (%) 21 (49)c 20 (47) 
TJC28, n (%) 7 (8·5)
c
 7 (8·9) 
Total mRSS 26 (5·9) 26 (7·2) 
Overall HAQ-DI score 1 (0·7) 1 (0·6)
e
 
Clinician global VAS 61 (15·2) 64 (15·1) 
CRP, mg/L 10 (13·5)
d
 10 (13·5) 
Platelet count, 10
9
/L 308 (88·9) 306 (82·4) 
% Predicted FVC 82% (13)
e
 80% (14) 
% Predicted DLCO (Hb corr) 74% (21)
c
 73% (19)
e
 
Patients with ≥1 digital ulcer,c n (%) 10 (23) 11 (26) 
a
Disease duration calculated from time of first non-Raynaud sign or symptom. 
b
See Appendix, Table S2 for additional information on previous and concomitant corticosteroid use 
c
Ulcer at or distal to the proximal interphalangeal joint, with loss of surface epithelialisation. 
d
n=43. 
e
n=42. 
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Data are mean (SD) unless stated otherwise. CRP=C-reactive protein; DLCO (Hb corr)=diffusing 
capacity for carbon monoxide corrected for haemoglobin; FVC=forced vital capacity; HAQ-
DI=Health Assessment Questionnaire–Disability Index; mRSS=modified Rodnan skin score; 
qw=every week; TJC28=tender joint count using 28 joints; VAS=visual analogue scale. 
Table 1: Baseline demographics and disease characteristics (safety population)  
 
 
PBO 162 mg qw 
SC  
n=44 
TCZ 162 mg qw 
SC  
n=43 
Difference in means 
TCZ-PBO  
(95% CI) 
p  
mRSS
 
 
Week 24 
–1·22 
n=43 
–3·92 
n=41 
–2·70  
(–5·85, 0·45) 
0·0915 
Week 48 
–2·77 
n=43 
–6·33 
n=41 
–3·55  
(–7·23, 0·12) 
0·0579 
HAQ-DI 
Week 24 
0·118 
n=42 
0·137 
n=41 
0·020 
(–0·186, 0·225) 
0·8503 
Week 48 
0·205 
n=41 
–0·002 
n=41 
–0·207 
(–0·471, 0·056) 
0·1212 
Clinician Global VAS  
Week 24 
–7·25 
n=41 
–8·24 
n=39 
–0·99 
(–9·20, 7·23) 
0·8118 
Week 48 
–9·39 
n=41 
–18·41 
n=40 
–9·02 
(–19·04, 1·00) 
0·0768 
Patient Global VAS 
Week 24 
1·53 
n=42 
–2·33 
n=42 
–3·85 
(–13·04, 5·34) 
0·4063 
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Week 48 
–2·70 
n=41 
–11·00 
n=42 
–8·30 
(–19·31, 2·71) 
0·1371 
FACIT (Fatigue) Score 
Week 24 
1·26 
n=41 
2·68 
n=42 
1·43 
(–2·97, 5·82) 
0·5197 
Week 48 
0·36 
n=40 
3·11 
n=42 
2·75 
(–1·38, 6·88) 
0·1886 
5-D Itch Scale 
Week 24 
–1·73 
n=41 
–0·94 
n=41 
0·79 
(–0·94, 2·51) 
0·3651 
Week 48 
–1·08 
n=40 
–2·19 
n=41 
–1·11 
(–3·16, 0·94) 
0·2841 
a
Negative change from baseline shows improvement for all efficacy measures, except for the FACIT-
Fatigue Scale, where positive change from baseline indicates improvement. A mixed-model repeated-
measures analysis was conducted that included the fixed categorical effects of treatment, visit, 
stratification factor of joint involvement at the baseline visit, and treatment-by-visit interaction and 
the continuous covariates of baseline score and baseline score-by-visit interaction. 
FACIT=Functional Assessment of Chronic Illness Therapy; HAQ-DI=Health Assessment 
Questionnaire– Disability Index; ITT=intent to treat; PBO=placebo; qw=every week; 
TCZ=tocilizumab; VAS=visual analogue scale. 
 
Table 2: Least square mean change from baseline
a
 to weeks 24 and 48 in mRSS 
(primary endpoint) and in patient- and physician-reported outcomes (ITT population)  
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AEs/SAEs, n (%)
a
 
Baseline to week 24 Baseline to week 48 
PBO 
162 mg qw 
SC  
n=44 
TCZ 
162 mg qw 
SC  
n=43 
PBO 
162 mg qw 
SC  
n=44 
TCZ 
162 mg qw 
SC  
n=43 
Total patients with ≥1 AE 40 (90·9) 38 (88·4) 40 (90·9) 42 (97·7) 
Total patients with ≥1 
infectious AE 
18 ( 40·9) 17 ( 39·5) 22 (50·0) 24 (55·8) 
Total patients with injection 
site reactions 
1 (2·3)
b
 2 (4·7)
c 2 (4·5)b 3 (7·0)c 
Total patients with ≥1 SAE 11 (25·0) 9 (20·9) 15 (34·1) 14 (32·6) 
Total patients with ≥1 
infectious SAE 
1 (2·3) 6 (14·0) 2 (4·5) 7 (16·3) 
Total patients with ≥1 non-
infectious SAE 
10 (23·0) 5 (11·6) 14 (31·8) 10 (23·3) 
Total patients who withdrew 
due to an AE 
5 (11·4) 4 (9·3) 5 (11·4) 6 (14·0) 
Deaths  1 (2·3) 1 (2·3) 1 (2·3) 3 (7·0) 
SAEs by SOC and preferred term
a
 
Infections and infestations 1 (2·3) 6 (14·0) 2 (4·5) 7 (16·3) 
Osteomyelitis 0 2 (4·7) 1 (2·3) 2 (4·7)d 
Bronchitis 0 1 (2·3) 0 1 (2·3) 
Cellulitis 1 (2·3)
e
 0 1 (2·3)
e
 0 
Infected skin ulcer 0 1 (2·3) 0 1 (2·3) 
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Lower respiratory tract 
infection 
1 (2·3)
e
 0 1 (2·3)
e
 0 
Lung infection 0 1 (2·3)
f
 0 1 (2·3)f 
Oesophageal candidiasis 0 1 (2·3) 0 1 (2·3) 
Pneumonia 0 0 0 1 (2·3)d 
Postprocedural cellulitis 0 0 0 1 (2·3) 
Sepsis 0 0 0 1 (2·3)d 
Cardiac disorders 3 (6·8) 0 4 (9·1) 1 (2·3) 
Acute myocardial 
infarction 
1 (2·3) 0 1 (2·3) 0 
Cardiac failure 1 (2·3) 0 1 (2·3) 0 
Cyanosis 1 (2·3) 0 1 (2·3) 0 
Arrhythmia 0 0 0 1 (2·3) 
Atrioventricular block 0 0 1 (2·3) 0 
Gastrointestinal disorders 2 (4·5) 0 4 (9·1) 1 (2·3) 
Colonic pseudo-obstruction 1 (2·3) 0 1 (2·3) 0 
Gastric antral vascular 
ectasia 
1 (2·3) 0 1 (2·3) 0 
Abdominal distension 0 0 1 (2·3) 0 
Abdominal pain 0 0 1 (2·3) 0 
Gastritis 0 0 0 1 (2·3) 
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Retroperitoneal fibrosis 0 0 1 (2·3) 1 (2.3) 
Musculoskeletal and 
connective tissue disorders 
2 (4·5) 0 2 (4·5) 2 (4·7) 
Scleroderma/systemic 
sclerosis (worsening) 
2 (4·5) 0 2 (4·5) 0 
Osteoarthritis 0 0 0 1 (2·3) 
Skin and subcutaneous tissue 
disorders 
0 1 (2·3) 1 (2·3) 2 (4·7) 
Skin ulcer 0 1 (2·3) 1 (2·3) 2 (4·7) 
Vascular disorders 2 (4·5) 1 (2·3) 2 (4·5) 1 (2·3) 
Hypertension 0 1 (2·3) 0 1 (2·3) 
Hypertensive emergency 1 (2·3) 0 1 (2·3) 0 
Raynaud’s phenomenon 1 (2·3) 0 1 (2·3) 0 
Blood and lymphatic system 
disorders 
1 (2·3) 1 (2·3) 1 (2·3) 1 (2·3) 
Haemolytic uraemic 
syndrome 
0 1 (2·3) 0 1 (2·3) 
Iron deficiency anaemia 1 (2·3) 0 1 (2·3) 0 
General disorders and 
administration site conditions 
0 1 (2·3) 0 2 (4·7) 
Impaired healing 0 1 (2·3) 0 1 (2·3) 
Multiorgan failure 0 0 0 1 (2·3) 
Nervous system disorders 0 0 2 (4·5) 0 
Headache 0 0 1 (2·3) 0 
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Subarachnoid haemorrhage 0 0 1 (2·3) 0 
Renal and urinary disorders 2 (4·5) 0 2 (4·5) 0 
Renal failure acute 1 (2·3) 0 1 (2·3) 0 
Scleroderma renal crisis 1 (2·3) 0 1 (2·3) 0 
Psychiatric disorders 0 1 (2·3) 0 1 (2·3) 
Psychotic disorder 0 1 (2·3) 0 1 (2·3) 
a
Total number of patients with ≥1 event; multiple occurrences of the same event in a patient were 
counted once. 
b
Grade 1 haematoma (baseline to week 24) and grade 1 injection site bruising (baseline to week 48). 
c
Two patients had grade 1 injection site erythema, and one patient had grade 2 injection site rash 
(baseline to week 24) and grade 1 contusion (baseline to week 24).
 
d
One TCZ patient who had osteomyelitis by week 24 subsequently had pneumonia and sepsis by week 
48.  
e
Both events occurred in the same patient. 
f
Event was fatal. 
AE=adverse event; qw = every week; SAE=serious adverse event; SOC=system organ class; 
TCZ=tocilizumab.  
 
Table 3. Safety  
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Figure 1: Patient disposition   
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Figure 2: Change from baseline in mRSS  
Δ LSM (TCZ-PBO): Difference in least-square means between treatment arms.  
Negative change represents an improvement. Means and 95% CI are from the repeated-measures 
model.
 
a
Non-responder assumption for missing data. Patients can be counted more than once. For example, a 
patient with a 40% improvement would be counted as a 20% responder and a 40% responder. 
b
p=0·2607. 
c
p=0·0685. 
d
p=0·0261. 
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Figure 3: Mean change from baseline 
Mean change from baseline in FVC (mL) at weeks 24 and 48 (A). Error bars show 95% 
confidence intervals for the means for each treatment arm. p value refers to treatment 
difference. Cumulative distribution of patients by change in percent predicted FVC from 
baseline to week 24 (B) and week 48 (C) (exploratory analysis).   
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Figure 4: Observed mean ± standard error serum levels of CCL18 (A), COMP (B), 
POSTN (C), and ENPP2 (D) (ng/mL) at baseline and at weeks 3, 8, 24, and 48 in 
patients treated with tocilizumab or placebo (exploratory analysis) plus  age- and 
gender-matched healthy controls (baseline only 
P value is for the overall treatment effect of tocilizumab versus placebo based on two-way 
analysis of variance with treatment, time, and treatment*time as factors. Serum CCL18, 
COMP, POSTN, and ENPP2 levels in healthy volunteers (triangles), tocilizumab-treated 
patients (squares), and placebo-treated patients (circles).   
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Figure 5: Unsupervised one-way clustering of the mean log10 normalized expression of 
83 genes measured using nCounter technology (Nanostring Technologies) in the skin 
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biopsies of 20 healthy controls and of 42 placebo baseline, 34 placebo week 24, 36 
tocilizumab baseline, and 29 tocilizumab week 24 patients. Shades of green denote low 
expression levels while shades of red denote high expression levels.  Genes significantly 
over or under expressed in SSc patients vs. healthy controls are marked by an asterisk. 
The 14 genes highlighted with arrows represent the genes specifically down regulated 
by TCZ at week 24 as compared to placebo (p < 0.05, analysis of covariance on 
difference in gene expression levels between week 24 and baseline with baseline 
expression levels as linear covariate and treatment as categorical predictor).  
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Figure 6. Mean ± Standard Error of the 2-Gene SSc Skin Biomarker predicted mRSS 
derived from the skin biopsy RNA samples from 42 placebo baseline, 33 placebo week 
24, 36 tocilizumab baseline and 29 tocilizumab week 24 patients; tocilizumab-treated 
patients (squares), and placebo-treated patients (circles).  P value is for the treatment 
effect of tocilizumab versus placebo based on an analysis of covariance on change in 
predicted mRSS with baseline predicted mRSS as linear covariate and treatment as 
categorical predictor. 
 
